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Abstract Visual hallucinations (VH) are common in
Parkinson’s disease (PD) and lead to a poor quality of life.
For a long time, dopaminergic therapy was considered to
be the most important risk factor for the development of
VH in PD. Recently, the cholinergic system, including the
pedunculopontine nucleus (PPN), has been implicated in
the pathophysiology of VH. The aim of the present study
was to investigate grey matter density of the PPN region
and one of its projection areas, the thalamus. Thirteen non-
demented PD patients with VH were compared to 16 non-
demented PD patients without VH, 13 demented PD
patients (PDD) with VH and 11 patients with dementia
with Lewy bodies (DLB). Isotropic 3-D T1-weighted MRI
images (3T) were analysed using voxel-based morphome-
try (VBM) with the PPN region and thalamus as ROIs. PD
and PDD patients with VH showed grey matter reductions
of the PPN region and the thalamus compared to PD
patients without VH. VH in PD(D) patients are associated
with atrophy of the PPN region and its thalamic target area,
suggesting that a cholinergic deficit may be involved in the
development of VH in PD(D).
Keywords Voxel-based morphometry  Visual
hallucinations  Parkinson’s disease  Neuroimaging
Introduction
Visual hallucinations (VH) in Parkinson’s disease (PD) are
a common non-motor symptom and constitute a major
source of distress to patients and caregivers. They lead to
increased disability, poor quality of life, and are a risk
factor for later dementia and nursing home placement [1–
3]. Conversely, cognitive impairment is an independent
risk factor for VH leading to a higher prevalence of VH in
demented PD patients (PDD) [2]. Furthermore, VH are also
a core feature of dementia with Lewy bodies (DLB) and,
therefore, may be associated with Lewy body pathology in
a broader sense [5].
In cross-sectional studies prevalence rates for major VH
in PD range from 22 to 38% while longitudinal studies
have shown that the prevalence of VH increases over time
reaching a life-time prevalence of up to 70% [2, 4].
Importantly, only a minority of PD patients report VH
spontaneously, probably leading to an underestimation of
the actual prevalence [2]. VH are also prevalent in DLB,
occurring in about 60% of patients [5].
Historically, dopaminergic therapy was considered to be
the most important risk factor for the development of VH
in PD. The mechanism of action was thought to be dopa-
minergic overstimulation of mesolimbic dopamine recep-
tors [6]. This hypothesis was supported by the powerful
effect of antipsychotics on VH by way of their antagonistic
activity on dopamine receptors [7]. Recently, changes in
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other neurotransmitter systems, in particular the choliner-
gic system, are considered as a possible cause of VH. The
cholinergic system plays a role in various cognitive func-
tions including attention, memory, cognitive shifting, and
sensory perception [8]. Disturbances in the cortical pro-
cessing of visual perception due to degeneration of cho-
linergic brain structures including the pedunculopontine
nucleus (PPN) are now believed to be involved in the
development of VH in PD [8, 9]. This is supported by
similarities in the phenomenology of VH in PD and those
occurring in peduncular hallucinosis, known to result from
damage to the midbrain and/or the thalamus [10].
Neuropathological studies in humans have reported that
at least 50% of the large cholinergic neurons of the lateral
part of the PPN, pars compacta, degenerate in PD [11]. The
PPN has also been implicated in the regulation of sleep and
REM-sleep behaviour disorder (RBD) [12]. Interestingly,
PD patients with VH have vivid dreams and nightmares
which may precede the onset of VH. Moreover, an asso-
ciation between RBD and VH has been suggested, linking
the PPN and VH in PD [13]. In contrast, the pathophysi-
ology of VH in DLB is considered to be related to Lewy
body pathology in cortical brain areas, especially in the
primary and secondary visual cortices [14].
So far, structural and functional studies addressing VH in
PD, PDD and DLB focused mainly on grey matter loss in
cortical areas, especially the primary visual system, the
visual association areas and frontal areas [15–19]. Several
voxel-based morphometry (VBM) MRI studies showed
involvement of these visual cortical areas in non-demented
and demented PD patients with VH [15, 16]. In addition, VH
in DLB and PDD were associated with decrease of volume in
frontal and associative visual areas in a recently published
study by Sanchez-Castan˜eda et al. [17]. Functional imaging
studies, including regional cerebral blood flow studies and
functional MRI studies, reported hypermetabolism or
increased cortical activation in the superior and inferior
frontal gyrus in combination with hypometabolism or
decreased cortical activation in the more posterior located
cortical visual areas in PD patients with VH [18, 19].
To our knowledge, no structural or functional studies
have addressed the involvement of the cholinergic output
structures of the midbrain in hallucinating demented and
non-demented PD patients [PD(D)] and DLB patients.
Therefore, the aim of the present retrospective study was to
investigate the PPN region and one of its projection areas,
the thalamus, by means of voxel-based morphometry in
these patients. We expected to find more pronounced grey
matter reductions of the PPN region and the thalamus in
PD(D) patients with VH compared to PD patients without
VH. Secondly, since cortical involvement by Lewy body
pathology is considered to occur early in DLB patients, we
predicted more pronounced decrease in cortical grey matter




Data were obtained in a retrospective manner from patients
who were referred to the outpatient clinic for Movement
Disorders at the VU University Medical Center, Amster-
dam, the Netherlands (PD and PDD patients) and from the
Alzheimer Center at the VU University Medical Center
(DLB patients). The MRI scans and neuropsychological
examinations used for this study, were part of the regular
diagnostic work-up. All patients gave a written informed
consent to store their medical information in a database and
to use these data for scientific research. Patients were
diagnosed by a movement disorder specialist (EF or HB)
according to the UK PD Brain Bank criteria [20] for idi-
opathic PD, and the Clinical Diagnostic Criteria for
Dementia Associated with Parkinson’s Disease [21] for
PDD. The diagnosis of DLB was made by the multidisci-
plinary team of the Alzheimer Center according to the
Consensus criteria for dementia with Lewy bodies [22] for
probable DLB.
The Mini-Mental State Examination (MMSE) [23] with
a cut-off value of \24 for dementia was used in cases where
an extensive neuropsychological examination was missing
(6 out of 13 patients). The severity of motor symptoms was
assessed using the Unified Parkinson’s Disease Rating
Scale-motor part (UPDRS-III) in the ‘‘on’’ state [24]. The
stage of the disease was determined using the Hoehn and
Yahr scale [25]. Patients were considered hallucinating if
they had experienced well-formed visual hallucinations of
people or animals for at least 4 weeks determined by means
of the Scales for Outcomes in Parkinson’s disease—Psy-
chiatric Complications (SCOPA-PC) [26] or by inquiry.
The levodopa equivalent dose was calculated as described
previously [27]. One (7.7%) PD ? VH patient, four
(30.8%) PDD ? VH patients, one (9.1%) DLB patient and
none of the PD–VH patients were taking antipsychotics
(clozapine or quetiapine). Five (38.5%) PDD ? VH
patients and four (36.4%) DLB patients were taking a
cholinesterase-inhibitor (rivastigmine).
Statistical analysis of the demographic and clinical
characteristics was carried out by the Statistical Package
for Social Sciences 15.0 (SPSS Inc, Chicago, Illinois,
USA). For normally distributed variables with homogene-
ity of variance, we performed one-way analysis of variance
(ANOVA) and post-hoc Tukey tests. For those variables
that did not meet normality, we used a non-parametric
Kruskal–Wallis test and a post-hoc Mann–Whitney U test
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with a Hochberg correction for multiple testing. Differ-
ences between groups were considered to be statistically
significant at P \ 0.05.
MRI acquisition and voxel-based morphometry
analysis
All MRI data were acquired on a 3.0 T GE Signa HDxt
scanner (General Electric, Milwaukee, Wisconsin, USA).
Prior to the volumetric analysis, the MRI scans were visually
checked. Scans with severe vascular white matter lesions
(Fazekas III) or extensive global cortical atrophy were
excluded. A 3-D structural MRI was obtained using a
T1-weighted FSPGR sequence with the following parame-
ters: TR (Repetition Time) = 7.8 ms; TI (Inversion Time) =
450 ms; TE (Echo Time) = 3.0 ms; 1 mm slice thickness;
FoV (field of view) = 25 cm; FA (flip angle) = 12o;
matrix = 256 9 256; voxel size = 1 9 0.94 9 0.94 mm.
Regional differences in grey matter volume were asses-
sed using VBM. The VBM analysis was performed with
SPM8 (Statistical Parametric Mapping, Wellcome Trust
Centre for NeuroImaging, Institute of Neurology, Univer-
sity College London, London, UK) running on Matlab 7
(Mathworks, Natick, Massachusetts, USA). The processing
included the following steps: images were reoriented by
placing the centre point on the anterior commissure and
were then segmented into grey matter, white matter and
cerebrospinal fluid (CSF). After automatic brain segmen-
tation the global volumes of grey matter, white matter and
CSF were calculated and an estimation of the total intra-
cranial volume (TIV) was made. A study-specific T1 MR
template was created from all participants using non-linear
registration and DARTEL [28] and the segmented images
were spatially normalised to this template. Subsequently,
the images were normalised to MNI (Montreal Neurological
Institute) space. A modulation step was added to maintain
the total amount of grey matter in each voxel after spatial
normalisation. The obtained modulated segmented images
were smoothed with an 8-mm full-width at half-maximum
isotropic Gaussian kernel.
To address our specific hypothesis and have sufficient
statistical power, we restricted our initial analysis to grey
matter regions of interest (ROIs) that were defined in the
thalamus and the PPN region. The ROI of the thalamus was
derived from the WFU Pick Atlas tool version 2.4 for SPM
[29]. The ROIs of the PPN region consisted of two 5 mm
spheres at MNI coordinates [±6.4 -27 -15]. These
coordinates are midpoints of the PPN derived from a ste-
reotactic localization study [30].
Regional differences in grey matter volume were
assessed from the smoothed and modulated grey matter
images using an ANOVA design as implemented in SPM8,
including age and TIV as covariates. Individual voxel and
cluster significance thresholds were set at P \ 0.05 cor-
rected for multiple comparisons (Family Wise Error).
After the masked VBM analysis with the PPN region
and thalamus, we also performed a whole brain VBM study
to determine the specificity of our findings. For whole brain
comparisons the threshold was set at an uncorrected
P \ 0.001 level.
Results
Clinical and demographical characteristics
We included 13 non-demented PD patients with VH
(PD ? VH), 16 non-demented PD patients without VH
(PD - VH), 13 demented PD patients with VH
(PDD ? VH), and 11 patients with dementia with Lewy
bodies (DLB). Demographic and clinical characteristics are
shown in Table 1. The four groups, PD patients with and
without VH, demented PD patients with VH and DLB
patients, did not differ in age at time of study or age at disease
onset. There were significant differences in disease duration
between PD patients without VH and PD(D) patients with
VH but no significant differences between PD patients with
VH and PDD patients with VH. PDD patients with VH were
more severely affected than PD patients with and without
VH, as reflected by a higher UPDRS-III score and H&Y
stage which was expected due to the natural disease pro-
gression. The MMSE-score ranged from 16 to 22 for PDD
patients without neuropsychological examination.
VBM results
The masked analysis revealed differences in grey matter
volume of the PPN region and the thalamus after covarying
for age and TIV as demonstrated in Table 2 for the dif-
ferent groups.
Hallucinating PD(D) patients versus non-hallucinating PD
patients
Hallucinating PD (PD ? VH and PDD ? VH) patients
showed significant clusters of reduced grey matter volume
compared to non-hallucinating PD (PD–VH) patients, both
in the PPN region and in the thalamus (Fig. 1). A restricted
comparison including only non-demented PD patients with
and without VH confirmed significant grey matter reduc-
tion related to VH in the PPN region, but not in the thal-
amus. However, using a lower statistical threshold of
uncorrected P \ 0.01 we did see an apparent trend of
volume reduction in the right thalamus in PD patients with
VH compared to PD patients without VH. Furthermore,
grey matter volume reductions in both the PPN region and
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thalamus were also present when comparing PDD patients
with VH to PD patients without VH (Table 2).
Hallucinating PD(D) patients versus DLB patients
No significant differences in grey matter volume of the
PPN region or thalamus were found between hallucinating
PD patients (PD ? VH or PDD ? VH) and DLB patients
using a FWE corrected threshold. However, a trend for
grey matter reduction of the PPN region was visible in
PD patients with VH compared with DLB patients and in
PDD patients with VH compared with DLB patients,
when using a lower threshold of uncorrected P \ 0.01
(Table 2).
Table 1 Demographical and clinical characteristics
PD - VH PD ? VH PDD ? VH DLB F/v2 P value
N = 16 N = 13 N = 13 N = 11
Sex (m/f) 9/7 6/7 7/6 11/0 9.90* 0.016a,b
Age (years) 64.3 ± 8.0 66.0 ± 6.9 67.7 ± 7.1 62.6 ± 6.5 1.42** 0.248 ns
Age at onset (years) 61.3 ± 7.4 54.5 ± 8.2 56.8 ± 9.4 58.0 ± 7.5 1.77** 0.165 ns
Disease duration (years) 3.1 ± 3.6 11.5 ± 5.2 10.9 ± 5.5 4.6 ± 4.5 23.7*** \0.001a,b,c,d
MMSE 28.9 ± 1.6 28.0 ± 1.7 21.2 ± 2.7 24.5 ± 1.4 26.8*** \0.001d,e,f
UPDRS-III 23.6 ± 11.5 29.1 ± 8.4 45.7 ± 15.9 na 13.7*** 0.001d,e
Hoehn & Yahr 2.1 ± 0.5 2.5 ± 0.3 3.5 ± 1.0 na 23.0*** \0.001c,d,e
Levodopa equivalent dose (mg) 170.2 ± 359.4 712.2 ± 380.8 68.4 ± 343.5 0.0 ± 0.0 29.8*** \0.001a,b,c,d




a Significant differences between PD ? VH and DLB after Hochberg correction for multiple testing
b Significant differences between PDD ? VH and DLB after Hochberg correction for multiple testing
c Significant differences between PD - VH and PD ? VH after Hochberg correction for multiple testing
d Significant differences between PD - VH and PDD ? VH after Hochberg correction for multiple testing
e Significant differences between PD ? VH and PDD ? VH after Hochberg correction for multiple testing
f Significant differences between PD - VH and DLB after Hochberg correction for multiple testing
Table 2 Group comparisons: ROI analysis
Regions Cluster level Voxel level T value
Cluster size P corrected MNI coordinates
x y z
VH \ non-VH Left PPN region 99 0.015 -4 -24 -12 4.55*
Right PPN region 121 0.013 6 -24 -15 4.06*
Left thalamus 31 0.019 -8 -13 0 4.15*
Right thalamus 9 0.033 9 -12 0 3.90*
PD ? VH \ PD–VH Left PPN region 53 0.020 -3 -25 -14 4.28*
Right PPN region 45 0.022 2 -25 -14 3.60*
Right thalamus 391 0.070 6 -13 1 3.24**
PDD ? VH \ PD–VH Left PPN region 74 0.017 -3 -25 -15 4.16*
Right PPN region 62 0.019 2 -25 -15 3.81*
Left thalamus 76 0.007 -9 -10 0 6.43*
PDD ? VH \ DLB Left PPN region 40 0.073 -4 -25 -9 2.94**
Right PPN region 28 0.081 8 -30 -14 2.82**
MNI coordinates refer to the location of the most statistically significant voxel in the cluster
* Significance threshold of P \ 0.05 corrected voxel-level for multiple comparisons (FWE)
** Significance threshold of P \ 0.01 uncorrected voxel-level
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Whole brain analysis
Grey matter reductions of the PPN region and thalamus were
also visible in the whole brain comparisons of hallucinating
PD patients (PD ? VH and PDD ? VH) with the non-hal-
lucinating PD patients and not in other brain areas. In addi-
tion, whole brain analysis of demented hallucinating patients
(DLB and PDD ? VH) compared with hallucinating PD
patients (PD ? VH) showed reduced grey matter volume of
the right middle frontal cortex (BA 10) (Fig. 2).
Discussion
The present study aimed to identify grey matter alterations
associated with VH in PD(D) and DLB. To our knowledge,
this is the first study which focused on brainstem and
thalamic regions rather than cortical areas. Our findings
support the hypothesis that the PPN region and thalamic
nuclei are involved in the pathophysiology of VH in Par-
kinson’s disease.
Recently, different models have been postulated to
explain the mechanisms of VH in PD. In the Perception and
Attention (PAD) model, which relates attention and object
perception deficits to VH, cholinergic inhibition gives a
greater chance to misperception of objects and allows the
intrusion of incorrect representations [31]. Dopamine is
also considered to mediate a net increase in signal-to-noise
ratio to maintain attention focus. However, given that
dopamine receptors are not prevalent in visual processing
areas, cholinergic dysfunction seems necessary to induce
VH [31]. In the early 1990s, Perry and co-workers [8]
reported the hallucinogenic character of anticholinergic
drugs. They mentioned that this was not necessarily a
cortical phenomenon but suggested instead a potential role
for the thalamic targets of the pedunculopontine-lateral
dorsal tegmental cholinergic nuclei [8]. This is particularly
Fig. 1 Grey matter volume reductions in hallucinating PD patients
(PD ? VH and PDD ? VH) compared to non-hallucinating patients
(PD–VH) obtained from a VBM analysis with selected regions of
interest. Results are overlapped in a normal TI-weighted image.
Clusters in a PPN and b thalamus reach significance at a corrected
cluster level (P \ 0.05 FWE)
Fig. 2 Grey matter volume reductions in demented hallucinating
patients (PDD ? VH and DLB ? VH) compared to non-demented
hallucinating PD patients (PD ? VH) obtained from a whole brain
analysis. Results are overlapped in a normal TI-weighted image.
Threshold was set at uncorrected level of P \ 0.001. Cluster of grey
matter volume reductions in demented patients is observed in right
middle frontal gyrus (BA 10)
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interesting when considering the cholinergic deficit
hypothesis for VH in PD. It is known that the PPN
degenerates in PD which may lead to impaired cholinergic
brainstem control of the cortex [10, 11]. Subsequently,
reduced cortical acetylcholine may lead to an inability to
suppress intrinsic cortical activity, which comes to con-
scious awareness in the form of VH [8].
Our results showed that hallucinating PD patients (both
demented and non-demented) had grey matter reductions in
the PPN and its thalamic targets compared to non-halluci-
nating PD patients. The comparison restricted to non-
demented PD patients with and without VH revealed grey
matter reduction of the PPN region but not of the thalamus.
One could interpret this as if volume loss of the thalamus is
the result of dementia rather than VH. However, we did find a
trend of grey matter reduction in the right thalamus of PD
patients with VH compared to PD patients without VH.
Furthermore, no significant differences were found in tha-
lamic grey matter volume between PDD and PD patients
with VH. These findings support the concept that atrophy of
both the PPN region and its thalamic projection area related
more strongly to VH than to concomitant cognitive decline.
However, although covariation for disease duration revealed
comparable results, the large difference in disease duration
between the hallucinating groups and the non-hallucinating
PD patients might influence the observed results and there-
fore only reflect natural disease progression.
Compared to DLB patients, hallucinating PD(D) patients
showed a trend of grey matter reductions of the PPN
region. Conversely, whole brain analysis showed reduced
grey matter volume of the right middle frontal cortex (BA
10) in hallucinating DLB and PDD patients compared to
hallucinating PD patients. This is line with the study of
Sa´nchez-Castan˜eda et al. [17] in which frontal involvement
in demented hallucinating patients (PDD and DLB) was
observed. However, because the hallucinating patients in
this study were also more demented compared to the non-
hallucinating control patients, it remains unclear whether
the differences in frontal cortex volume were not con-
founded by the concomitant dementia and not related to
VH per se. Nevertheless, one may consider that the PPN
region plays an important role in provoking VH in
PD(D) while in DLB, VH are primarily the result of other
cholinergic output structures.
The previously reported grey matter loss of visual cor-
tical areas (gyrus lingualis and superior parietal lobe) in
hallucinating non-demented PD patients were not observed
in the present study [15]. This may be due to differences in
general cognitive status as reflected by a difference in mean
MMSE score between our non-demented PD patients and
the PD patients in the study of Ramirez-Ruiz et al.,
reflecting a more advanced disease stage. This is supported
by the absence of cortical grey matter volume changes in
hallucinating non-demented PD patients in the recently
published study by Meppelink et al. [32].
Based on our results, we hypothesize that degeneration
of the PPN in PD influences thalamocortical activity
hereby decreasing the arousal state and hence leading to
VH. The decrease in volume of visual association areas and
frontal areas described in other VBM studies may be
interpreted as being secondary to the PPN degeneration.
However, neuropathological confirmation is necessary to
establish this hypothesis. Until now, neuropathological
studies did not consider brainstem structures to be a
potential neural substrate of VH in PD but focussed on
cortical structures. More Lewy body (LB) pathology was
observed in the amygdala and parahippocampus in PD
patients with VH compared to those without VH [33]. One
study reported that cases presenting with VH early in the
disease course have more LB pathology within the tem-
poral cortex [34]. However, these cortical changes may be
related to dementia because most of the patients included
were also demented. In addition, VH early in the disease
course are suspect for the diagnosis of DLB. As previously
suggested, VH in DLB patients may result from degener-
ation of other cholinergic brain structures. In this respect,
one may consider the basal forebrain structure nucleus
basalis of Meynert (nBM) [35]. This is supported by a
neuropathological study showing a relationship between
neuronal loss and LB formation in the nBM and inverse
decrease in neocortical choline acetyltransferase activity
[36]. In addition, one study addressed the degeneration of
the PPN in DLB. Loss of cholinergic neurons in DLB
patients was less severe than in MSA patients, the latter
patients being cognitive intact and not suffering from VH
[37]. Although speculative, this may suggest that VH in
DLB patients are more related to degeneration of the nBM
than to degeneration of the PPN compared to PDD patients
with VH.
Limitations of the study
Firstly, the relatively small sample size and the unmatched
patient characteristics of the different groups in the present
retrospective study limits the generalization of the results
and, therefore, the results should be interpreted as pre-
liminary. However, whole brain analysis performed as
post-hoc analysis showed comparable significant clusters
of grey matter reduction of the PPN region and thalamus
and not in other brain areas, indicating the specificity of the
obtained results. Secondly, due to the dichotomous mea-
sure of VH, we could not correlate the degree of grey
matter reduction with the severity of VH. Another limita-
tion is the small volume and the not-well defined bound-
aries of the PPN. Because the brainstem has a high density
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of nuclei at this level, we could not be absolutely sure
about interference of neighbouring nuclei of the PPN
region including the more medial located laterodorsal
tegmental nuclei (LDTN). This is of particular interest
because the LDTN mainly consists of cholinergic neurons
and immunohistochemical studies have shown that
85–95% of brainstem afferents to most thalamic nuclei
originate from cholinergic neurons in the rostral brainstem
where the PPN and the LDTN are maximally developed
[38]. However, using two small 5 mm spheres at the
midpoint of the PPN derived from a stereotactic localiza-
tion study makes it unlikely that the LDTN has been
included in the ROI.
In conclusion, we found reduced grey matter in the PPN
region and the thalamus in hallucinating PD(D) patients,
which suggests that degeneration of the PPN may con-
tribute to VH in PD(D). This supports that the cholinergic
system may be important when considering new treatment
strategies for VH in PD. Further studies combining struc-
tural and functional imaging with special focus on the
cholinergic system in larger patient groups are needed.
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